Overview
- The company announced on Thursday, July 30, 2026, that it closed a $200 million Series B led by Greenoaks at a reported $2 billion valuation with participation from Index, Hanabi, Bain Capital Ventures, A*, Factory, Definition, and CVS Health Ventures.
- Simile, which spun out of Stanford and was founded by Joon Sung Park, builds foundation models that generate synthetic, human-like agents and simulated societies trained on human interaction data for use in marketing, product research, financial modeling, and policy testing.
- CVS Health is reported as a marquee customer that used Simile’s models to study prescription adherence by comparing agentic twins to responses from a 1,000-person interview panel and a larger 400,000-person dataset, according to coverage of the company’s work.
- Reporters and experts flag technical limits and ethical risks: critics question how accurately models can capture human unpredictability and emotion and warn about privacy, data provenance, inference risks, and the potential to replicate historical biases in synthetic outputs.
- Simile says it has no token or blockchain strategy, and the fresh funding will support product development such as a claimed confidence model to estimate simulation accuracy while drawing investor interest that could reshape how companies run consumer tests and policy experiments.